Merck MRK is focusing on driving long-term growth through the newer products and a promising set of pipelines as its blockbuster PD-1 inhibitor, Keytruda, approaches patent expiration in 2028.

Now, the person making the call is somebody somewhere who works for (the insurance company). It’s not my physician, who’s an ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced KEYTRUDA® (pembrolizumab) plus ...

Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without bevacizumab, improves survival in platinum-resistant ovarian cancer. The phase 3 KEYNOTE B96 trial ...

Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our ...

The two blockbusters have made a big difference in bladder cancer survival, but will their chemistry hold up when tested in other types?

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

While Johnson & Johnson retains the top revenue rank across the major pharma companies, Eli Lilly last year established ...

The trial enrolled 1,841 patients and measured DFS, with safety, OS, and quality of life as secondary endpoints.

After a surprise failure in advanced liver cancer, Merck & Co. and Eisai are hoping new data can make their Keytruda-Lenvima combination a standard of care in intermediate-stage disease. The positive ...